ReviewNeuroscience and biobehavioral reviews2010
Translating the neuroscience of alcoholism into clinical treatments: from blocking the buzz to curing the blues.
Review in Neuroscience and biobehavioral reviews, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 62 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Traits Associated With Early Life Stress Among Treatment-Seeking Alcoholics
(Epi)Genetic Modulators of Fear Extinction in Alcohol Dependence
Who cites it
62 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A meta-regression of methodological features that predict the effects of medications on the subjective response to alcohol.Alcoholism, clinical and experimental research · 2021Pooled it
- Naltrexone effects on subjective responses to alcohol in the human laboratory: A systematic review and meta-analysis.Addiction biology · 2019Pooled it
- Nalmefene attenuates neural alcohol cue-reactivity in the ventral striatum and subjective alcohol craving in patients with alcohol use disorder.Psychopharmacology · 2021Trial
- Precision Medicine in Alcohol Dependence: A Controlled Trial Testing Pharmacotherapy Response Among Reward and Relief Drinking Phenotypes.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018Trial
- Development of the Neuroimmune Modulator Ibudilast for the Treatment of Alcoholism: A Randomized, Placebo-Controlled, Human Laboratory Trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017Trial
- Effects of naltrexone are influenced by childhood adversity during negative emotional processing in addiction recovery.Translational psychiatry · 2017Trial
- Subjective responses to alcohol in the lab predict neural responses to alcohol cues.Journal of studies on alcohol and drugs · 2014Trial
- Interactive effects of OPRM1 and DAT1 genetic variation on subjective responses to alcohol.Alcohol and alcoholism (Oxford, Oxfordshire)Trial
- Functional remodeling of the parasubthalamic nucleus drives alcohol drinking escalation in dependence.bioRxiv : the preprint server for biology · 2026Article
- Modification of inhibitory control and craving through transcranial direct current stimulation as an add-on treatment for substance use disorder: protocol for a randomized controlled study.BMC psychology · 2025Article
- Dynamic symptom networks in etomidate use disorder: a cross-lagged panel network analysis of craving, compulsive drug seeking, and cognitive control.Frontiers in public health · 2025Article
- Laboratory and Real-World Experimental Approaches to Understanding Alcohol Relapse.Current topics in behavioral neurosciences · 2025Review
- Reducing stress and alcohol-related behaviors by targeting D1-CRHR1 receptor interactions in the amygdala.Frontiers in pharmacology · 2025Article
- Modeling Aversion Resistant Alcohol Intake in Indiana Alcohol-Preferring (P) Rats.Brain sciences · 2022Article
- Relating Compulsivity and Impulsivity With Severity of Behavioral Addictions: A Dynamic Interpretation of Large-Scale Cross-Sectional Findings.Frontiers in psychiatry · 2022Article
- Evaluation of the Addictions Neuroclinical Assessment (ANA) framework through deep phenotyping of problem drinkers.Drug and alcohol dependence · 2021Article
- The Role of the Central Amygdala in Alcohol Dependence.Cold Spring Harbor perspectives in medicine · 2021Review
- Do behavioral pharmacology findings predict clinical trial outcomes? A proof-of-concept in medication development for alcohol use disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021Article
- A study on the correlates of habit-, reward-, and fear-related motivations in alcohol use disorder.CNS spectrums · 2019Article
- Compulsivity in Alcohol Use Disorder and Obsessive Compulsive Disorder: Implications for Neuromodulation.Frontiers in behavioral neuroscience · 2019Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Understanding the pathophysiology of addictive disorders is critical for development of new treatments. A major focus of addiction research has for a long time been on systems that mediate acute positively reinforcing effects of addictive drugs, most prominently the mesolimbic dopaminergic (DA) system and its connections. This research line has been successful in shedding light on the physiology of both natural and drug reward, but has not led to therapeutic breakthroughs. The role of classical reward systems is perhaps least clear in alcohol addiction. Here, recent work is summarized that points to some clinically important conclusions. First, important pharmacogenetic differences exist with regard to positively reinforcing effects of alcohol and the ability of this drug to activate classical reward pathways. This offers an opportunity for personalized treatment approaches in alcoholism. Second, brain stress and fear systems become pathologically activated in later stages of alcoholism and their activation is a major influence in escalation of alcohol intake, sensitization of stress responses, and susceptibility to relapse. These findings offer a new category of treatment mechanisms. Corticotropin-releasing hormone (CRH) signaling through CRH1 receptors is a major candidate target in this category, but recent data indicate that antagonists for substance P (SP) neurokinin 1 (NK1) receptors may have a similar potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.